Personalized Medicine and Pharmacogenomics: Revolutionizing Healthcare through Precision Treatment Approaches
Keywords:
Healthcare, Personalized Medicine, Drug ResponseAbstract
Personalized medicine and pharmacogenomics have emerged as groundbreaking paradigms in healthcare, aiming to tailor medical interventions and drug therapies to individual patient characteristics. This review paper explores the concepts of personalized medicine and pharmacogenomics, delves into their applications across various medical fields, discusses challenges and ethical considerations, and concludes with a perspective on their transformative potential for the future of healthcare.
How to cite this article:
Personalized Medicine and Pharmacogenomics:
Revolutionizing Healthcare through Precision
Treatment Approaches. Int J Adv Res Med Chem
2023; 5(1): 15-18
References
Ginsburg, Geoffrey S, and Huntington et.al “Genomic and personalized medicine: foundations and applications.” Translational Research 2009; 154(6): 277-287.
Hamburg, Margaret A., and Francis S. Collins. “The path to personalized medicine.” New England Journal of Medicine 2010; 363(4): 301-304.
Relling, Mary V, and William E. “Pharmacogenomics in the clinic.” Nature 2015; 526(7573): 343-350.
Pereira, Nuno L., and Rui Medeiros. “Development and application of pharmacogenomics in the era of precision medicine.” Human Genetics 2017; 136(11-12): 1429- 1444.
Vogenberg, F Randy, and Philip E Santilli. “Personalized medicine: part 1: evolution and development into theranostics.” Pharmacy and Therapeutics 2012; 37(12): 704.
Swen, Jesse J., E. Rogier van der Weide, et.al “Pharmacogenetics: from bench to byte—an update of guidelines.” Clinical Pharmacology & Therapeutics 2011; 89(5): 662-673.
Collins, Francis S., and Eric D. Green. “A vision for the future of genomics research.” Nature 2003; 422(6934):
-847.
Manolio, Teri A., Francis S. Collins, and National Academies of Sciences, Engineering, and Medicine. “The role of the National Institutes of Health in advancing the science of health disparities.” JAMA 2020; 323(7): 601-602.
McLeod, Howard L., and Mary V. Relling. “Genome-wide studies for predicting drug response.” Pharmacogenomics 2012; 13(12): 1467-1470.
Hamburg, Margaret A. “FDA’s approach to regulation of products of nanotechnology.” Science 2012; 336 (6079): 299-300.
Crews, Kristine R., and Richard M. Gaedigk. “Impact of genome-wide genotyping on the prediction of pharmacokinetics.” Clinical Pharmacology & Therapeutics 2011; 89(3): 416-418.
Sadee, Wolfgang, and Frank J. Gonzalez. “Pharmacogenomics of the human OME.” Pharmacology & therapeutics 2013; 137(3): 297-315.
Bush, William S., Marylyn D. et.al “Electronic health records-based phenotyping.” Genetic epidemiology 2013; 37(1): 72-86.
Lazarou, Jason, Bruce H. Pomeranz, et.al. “Incidence of adverse drug reactions in hospitalized patients: a meta-
analysis of prospective studies.” Jama 1998; 279(15): 200-1205.
Shuldiner, Alan R., Dan M. Roden, et.al“The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.” Clinical pharmacology and therapeutics 2019; 106(1): 94-102.
